Aerovate Therapeutics Inks $72.6M Series A
Aerovate Therapeutics Inks $72.6M Series A Back to HomeBOSTON, MA, Aerovate Therapeutics has closed on $72.6 million in Series A funding. Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). The Series A for Aerovate, which was founded and incubated by RA Capital Management, is led by Sofinnova Investments, a new investor in the company. "Aerovate is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.